| Document |
Document Title |
|
WO/2022/100722A1 |
A 5,6-epoxy sterol compound intermediate, and a preparation method therefor and an application thereof. The intermediate has a chemical structure represented by formula I, wherein R is selected from -CH 2OCOR 1 or -CH＝CH-CO(O)R 1, and ...
|
|
WO/2021/214685A1 |
The present invention refers to a method for the preparation of a compound of formula (I).
|
|
WO/2021/109791A1 |
A method for synthesizing ursodeoxycholic acid, comprising: taking a plant-derived compound BA as a raw material, and synthesizing ursodeoxycholic acid by the steps of ethylene glycol or neopentyl glycol protection, oxidation, Wittig rea...
|
|
WO/2021/069570A1 |
Compounds and compositions for the activation of SERCA2a are disclosed. In particular, provided are compounds that act as predominantly pure or pure SERCA2a activators while only moderately inhibiting the Na+/K+ ATPase. In general, the d...
|
|
WO/2020/264512A1 |
Provided herein in part is a compound of Formula (I): or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of Formula I, and methods of using the compounds, e.g, in the treatment of CNS- relate...
|
|
WO/2020/264495A1 |
Provided herein is a compound of Formula (1-I): or a pharmaceutically acceptable salt thereof, wherein R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, R11a, R11b, R16a, R16b, R19, R18, X, q, r, s, t, u, and n are defined herein. Also provided here...
|
|
WO/2020/243488A1 |
Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1a, R1b, R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, R7a, R7a, R11a, R11b, R12a, R12b, R16a, R16b, R19, R11a, R22, RX, RY and n are defined he...
|
|
WO/2020/132504A1 |
Provided herein is a compound of Formula (I) or pharmaceutically acceptable salt thereof, wherein R2a, R2b, R4a, R4b, R6, R7, R11a, R11b, R16, R17, R3, R5, R19 and RX are defined herein and wherein RY represents optionally substituted he...
|
|
WO/2020/082065A1 |
Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein n, R19, R5, R3, R6a, R6b, R2a, R2b, R4a, R4b, R7a, R7b, R11, R12a, R12b, R16, R21a, R21b, and R21c are defined herein. Also provided here...
|
|
WO/2020/077255A1 |
Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein n, R19, R5, R3a, R6a, R6b, R1, R2a, R2b, R4a, R4b, R7a, R7b, R11a, R11b, R12a, R12b, R17b, R15a, R15b, R16a and R16b are defined herein. ...
|
|
WO/2019/126741A1 |
Provided herein are compounds of Formula (I-I): and pharmaceutically acceptable salts thereof; wherein p, R1, R3a, R2a, R11a, R11b, R6a, and R6b are defined herein. Also provided herein are pharmaceutical compositions comprising a compou...
|
|
WO/2017/199033A1 |
The invention relates to compounds of general formula (I): wherein: R1,R2, R3, R4, R5, R6 and Y are as defined herein. The compounds are intermediates in the synthesis of synthetic bile acids which are useful in the treatment of conditio...
|
|
WO/2017/199039A1 |
The invention relates to a process for preparing a compound of general formula (Ia): wherein R2, Y, R4 and R5 are as defined herein. The invention also relates to certain compounds per se. The compounds are intermediates in the synthesis...
|
|
WO/2017/174515A1 |
The invention relates to a process for preparing a compound of formula (I) in particular obeticholic acid and intermediates suitable for its synthesis.
|
|
WO/2017/149091A1 |
The invention relates to a process for the preparation of 11 -methylene steroids through selective olefination of the ketone at position 11. The resulting products are useful intermediates in the preparation of several pharmaceutically a...
|
|
WO/2017/149052A1 |
The invention pertains to a process for producing a compound of formula (11) wherein R7 and R8 are each independently selected from H, halogen, alkyl, aryl, or alkylaryl, R42 is H or a protective group, R43 is H or R3, wherein R3 is a pr...
|
|
WO/2017/027396A1 |
The present application relates to a method of preparing compounds of Formula (A) or a pharmaceutically acceptable salt, solvate, or amino acid conjugate thereof.
|
|
WO/2016/165496A1 |
Disclosed is method for preparing a deoxycholic acid or ester thereof or pharmaceutically acceptable salt thereof. The compound is suitable for removing fat deposition.
|
|
WO/2016/090139A1 |
Described herein are compositions and methods for hormone replacement therapy that address the shortcomings of the existing methods. Described herein are pharmaceutically effective partial agonistic antiprogestins. The combined applicati...
|
|
WO/2016/044559A1 |
The present invention relates to C-20 steroid compounds, compositions and methods of use thereof to treat, minimize and/or prevent traumatic brain injury (TBI), including severe TBI, moderate TBI and mild TBI, including concussions.
|
|
WO/2014/127201A1 |
The present disclosure is generally directed to neuroactive enantiomeric 15-, 16- and 17- substituted steroids with additional optional substituents at carbons 3, 4, 6, 7, 10 and 13, and pharmaceutically acceptable salts thereof, for use...
|
|
WO/2014/037873A1 |
There is described a process for the industrial synthesis of 11-methylene-18- methyl-estr-4-en-3, 17-dione, a compound having the structure formula (I) depicted below: (Formula I) (I) useful as intermediate compound in the synthesis of t...
|
|
WO/2013/078575A9 |
Disclosed is a preparation method of 5,7-pregnadiene-3,20-dione-diethyl ketal. The preparation method comprises: performing dehydration condensation on progesterone by using glycol to protect two carbonyls, so as to obtain a compound B; ...
|
|
WO/2013/063859A1 |
Provided are an Ulipristal acetate (compound I) preparation method, a novel key intermediate (compound of formula IV) for preparing the Ulipristal acetate and preparation of the key intermediate. It has been surprisingly found in the pre...
|
|
WO/2013/016725A1 |
Described herein are compounds which either act as pure antiprogestins or as antiprogestins with partial agonistic activity and methods of treating cancer using such compounds.
|
|
WO/2012/061954A1 |
The preparative method of zingiberensis saponin with structure as followed (I) extracted from Dioscorea zingiberensis comprises steps as followed: extracting the tuber of Dioscorea zingiberensis C. H. Wright. as raw material using one or...
|
|
WO/2012/047495A2 |
This invention relates generally to methods for preparing certain bile acids from non-mammalian sourced starting materials as well as to synthetic bile acids and compositions comprising such acids wherein the acids are characterized by a...
|
|
WO/2011/157443A1 |
The present invention relates to (11β,17α)-11-(4-(2-11C-acetyl)phenyl)-17,23- epoxy-19,24-dinorchola-4,9,20-trien-3-one, an 11C-labelled ORG 33628; a process for the preparation thereof, intermediates used in this process and the use o...
|
|
WO/2011/075701A2 |
Synthetic methods for preparing deoxycholic acid and intermediates thereof, high purity synthetic deoxycholic acid, compositions and methods of use are provided. Also, provided are processes for the synthesis of 12-keto or 12-α-hydroxys...
|
|
WO/2010/118560A1 |
The invention provides a process for preparing eplerenone, which comprises the following steps: (1) in the presence of a side reaction inhibitor, 17α-hydroxyl-3-oxo-γ-lactone-pregn-4,9(11)-diene-7α,21-di
carboxylic acid methyl ester I...
|
|
WO/2010/118025A1 |
Described herein are compounds which exhibit progesterone antagonistic effects and methods of treating cancer using such compounds.
|
|
WO/2010/118023A1 |
Described herein are methods of making drospirenone. Also described are intermediate compounds that may be used to synthesis drospirenone.
|
|
WO/2010/000070A1 |
The present invention relates to a process for extracting, purifying and isolating cyclopamine from cyclopamine-containing biomass comprising the steps of contacting cyclopamine-containing organic matter with an extractant (e.g., aqueous...
|
|
WO/2009/124460A1 |
The invention discloses Tripterygium wilfordii diterpene lactone derivatives represented by formula (1), their optical isomers and pharmaceutically acceptable salts and hydrates. The invention also provides pharmaceutical compositions an...
|
|
WO/2009/083268A2 |
The invention relates to 17-(1'-propenyl)-17-3'-oxidoestra-4-en-3-one derivatives with general chemical formula (1) wherein the radicals Z, R4, R6a, R6b, R7, R15, R16a, R16b and R18 have the designations given in claim 1, and to the solv...
|
|
WO/2008/155534A9 |
The present invention relates to novel neurosteroid derivatives with anti-apoptotic, neuroprotective and neurogenic properties that act on the nervous system as well as methods for making the same and their applications in the treatment ...
|
|
WO/2009/004394A2 |
The present invention relates to a novel selective synthesis of 9α-hydroxy-steroid derivatives of the general formula (I) (I) - wherein the meaning of -A-A'- is -CH2-CH2- or -CH=CH- group - by the bioconversion of compounds of the gener...
|
|
WO/2009/001148A2 |
The present invention relates to a process for the synthesis of the known 17-acetoxy-11-β-[4-(dimethylamino)-phenyl]-21-methoxy-19-no
rpregna-4,9-dien-3,20-dione (further on CDB-4124) of formula (I) from 3,3-[1,2-etandiyl-bis(oxy)]-oest...
|
|
WO/2008/058767A1 |
The present invention relates to progesterone receptor antagonists of general formula I: in which R1 can be a hydrogen atom and R2 a hydroxyl group or R1 and R2 together can be an oxo group.
|
|
WO/2008/011005A2 |
Compositions and methods for treating mammalian diseases or conditions characterized by abnormal cell mitosis and/or abnormal or undesirable angiogenesis, by administering an effective amount of analogs of 2-methoxyestradiol. Compounds t...
|
|
WO/2007/144674A1 |
The present invention relates to a new industrial process for the synthesis of solvate- free 17α-acetoxy-11β-[4-(N,N-dimethyl-amino)-phenyl]-19-norpreg
na-4,9-diene-3,20-dione [CDB -2914] of formula (I) which is a strong antiprogestoge...
|
|
WO/2007/118717A2 |
The present invention relates to a method for the reliable and reproducible preparation of 4-[17β-methoxy-17α-methoxymethyl-3-oxoestra-4,9-dien-llβ-
yl]benzaldehyde (E)-oxime (asoprisnil) on the pilot and manufacturing scale. Asopris...
|
|
WO/2007/025780A2 |
Compounds of the formula (I), (R1 is one of a wide range of substituents; R2 = H, halogen and R3 = H, hydroxymethyl or CR2R3 = cyclopropyl ring; CR4R5 is one of formula (II), formula (III) and formula (IV) Ra and Rb are a bond between ca...
|
|
WO/2007/004090A2 |
The present invention relates to processes for the prepartion of purified solanesol, solanesyl bromide & solanesyl acetone. Solanesyl acetone has the chemical name - all - trans 6, 10, 14, 18, 22, 26, 30, 34, 38 -nonamethyl -5,9, 13, 17,...
|
|
WO/2006/062129A1 |
A process for producing (5&agr ,7&agr )-3-spiro-2'-(1',3'-dioxolan)-24-oxocholest-22-en-7-yl benzoate (unsaturated ketone (I)), which is represented by the formula (I), (I) characterized by dissolving in methanol a crude reaction product...
|
|
WO/2006/052263A1 |
Methods for separation and synthesis of the optically active 7-thioester isomers and mono or bis-cyclopropyl derivatives of spironolactone are provided. Preferred stereoisomerically purified 7-thioester isomers and mono or bis-cyclopropy...
|
|
WO/2006/045745A1 |
A process is described for preparing, exclusively by chemical way, 21-hydroxy steroids having progestinic activity, said process having a high stereochemical control at C-21 position.
|
|
WO/2006/032970A2 |
Processes are described for the conversion of a steroid substrate having a 4,7-carbonyl bridge to a structure comprising a 7&agr -alkoxycarbonyl substituent by reaction of the substrate with an alkoxy group source, preferably in the pres...
|
|
WO/2005/092913A1 |
Processes are described for epoxidation reactions. In particular, the process comprises the conversion of a steroid substrate having an olefinic unsaturation in the steroid nucleus to a structure comprising a 9,11-epoxy substituent by re...
|
|
WO/2004/089304A2 |
The instant invention provides potent antiandrogen compounds, such as 3β -acetoxyandrost-1,5-diene-17-ethylene ketal and 3β-hydroxyandrost-1, 5-diene-17ethylene ketal, and methods for their use in the prevention and treatment of biolog...
|
